US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by SonoThera
Fierce Biotech, a Division of Forge, Names SonoThera a “Fierce 15” Biotech Company of 2026
October 05, 2026
From
SonoThera
Via
Business Wire
SonoThera Appoints Adam J. Shaywitz, M.D., Ph.D., as Chief Medical Officer
September 14, 2026
From
SonoThera
Via
Business Wire
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines
June 10, 2026
From
SonoThera
Via
Business Wire
SonoThera to Present Non-Viral RIPPLE™ Platform Data Demonstrating Multi-Tissue Delivery and Gene Expression at ASGCT 2026
May 05, 2026
From
SonoThera
Via
Business Wire
SonoThera Presents New Preclinical Data at MDA 2026 Highlighting RIPPLE™ as an Efficient, Scalable, Nonviral Platform for Full-Length Dystrophin Delivery in DMD
March 05, 2026
From
SonoThera
Via
Business Wire
SonoThera Launches $125M Series B at 44th J.P. Morgan Healthcare Conference to Advance Multiple Genetic Medicine Programs Toward First-in-Human Studies
January 08, 2026
From
SonoThera
Via
Business Wire
SonoThera Presents New Data at ASH 2025 Demonstrating Durable Factor VIII Expression Using Ultrasound Mediated Gene Delivery in Treating Hemophilia A
December 08, 2025
From
SonoThera
Via
Business Wire
SonoThera Presents New Data at ASN Kidney Week 2025 Demonstrating Full-Length Col4a5 Gene Expression Using Ultrasound Mediated Gene Delivery in Treating X-Linked Alport Syndrome
November 05, 2025
From
SonoThera
Via
Business Wire
SonoThera™ Presents New Data at ESGCT 2025 Demonstrating Expression of Full-Length Human Dystrophin Using Targeted, Ultrasound-Mediated Delivery to Treat Duchenne Muscular Dystrophy
October 07, 2025
From
SonoThera
Via
Business Wire
SonoThera™ to Present New Data at ASGCT 2025 Demonstrating the Potential of Genetic Medicine Using Targeted, Ultrasound-Mediated Delivery in Treating Duchenne Muscular Dystrophy and Hemophilia A
May 06, 2025
From
SonoThera
Via
Business Wire
SonoThera Presents New Data at the 2025 MDA Conference Demonstrating the Potential of Genetic Medicine Using Targeted, Ultrasound-Mediated Delivery (UMD) in Treating Duchenne Muscular Dystrophy
March 10, 2025
From
SonoThera
Via
Business Wire
SonoThera to Present Preclinical Data on Ultrasound-Mediated Gene Delivery Platform to the Heart at the American Heart Association (AHA) Scientific Sessions 2024
November 11, 2024
From
SonoThera
Via
Business Wire
SonoThera to Present at ASN Kidney Week 2024 Demonstrating the Potential of Novel Nonviral Ultrasound-Mediated Gene Therapy Delivery Platform
October 22, 2024
From
SonoThera
Via
Business Wire
SonoThera™ Receives Exclusive Licensing of GE HealthCare’s Optison® and Sonazoid® Microbubble Products for use with its Ultrasound-guided Gene Therapy Platform
February 27, 2023
From
SonoThera
Via
Business Wire
SonoThera™ Completes $60.75M Series A Funding for Ultrasound-Guided, Nonviral Gene Therapy Platform Development
December 05, 2022
From
SonoThera
Via
Business Wire
